Immunome, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Immunome, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 833% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 89% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-4.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 56% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
+30%Cash, after subtracting all debt, equals 30% of its market value (net cash).
Higher than 68% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Immunome, Inc. made a loss over the last year. Immunome, Inc. owes $0.07 for every $1 it owns. Immunome, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossImmunome, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
4.04The share price is 4.04 times Immunome, Inc.'s book value per share, higher than 65% of Healthcare companies in United States.
Market cap
$2.1 BThe total market value of all of Immunome, Inc.'s shares at today's price (share price × number of shares), larger than 76% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$525 MWhat Immunome, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.45Net worth divided by the number of shares. The share price of $17.99 is 4.0 times this, which is the P/B above.
Return on equity (ROE)
-64.0%Immunome, Inc. lost 64.0% of its shareholders' money over the last year, lower than 58% of Healthcare companies in United States.
Owes vs Owns
0.07×Immunome, Inc. owes $0.07 for every $1 it owns (low), lower than 92% of Healthcare companies in United States.
Dividend yield
NoneImmunome, Inc. does not currently pay a dividend.
Revenue growth
-23%Revenue fell 23% in the year to Dec 2025.
Profit growth
LossImmunome, Inc. made a loss in each of the last two years.
Profit margin
-3060.0%Immunome, Inc. lost $3060 for every $100 of revenue.
Cash vs debt
Net cashImmunome, Inc. held $650 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Immunome, Inc.: $2.1 B ÷ $525 M (30 Jun 2026) = 4.0.
What is Immunome, Inc.'s return on equity?
Immunome, Inc. lost 64.0% of its shareholders' money over the last year, lower than 58% of Healthcare companies in United States.
How much does Immunome, Inc. owe compared with what it owns?
Immunome, Inc. owes $0.07 for every $1 it owns (low), lower than 92% of Healthcare companies in United States.
Does Immunome, Inc. pay a dividend?
No. Immunome, Inc. does not currently pay a dividend.
Is Immunome, Inc.'s revenue growing?
Revenue fell 23% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.